NeuroVive Pharmaceutical AB: European Phase III Study Approaches Its Final Stage
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
NeuroVive Pharmaceutical AB (publ), a leading mitochondrial medicine company, announces that the ongoing international multicenter phase III study on the company´s drug candidate CicloMulsion® (the CIRCUS study) for the treatment of reperfusion injury in connection with heart attack is continuing according to plan and is approaching its final stage. If nothing unexpected occurs the study is estimated to be completed near the end of 2014, when the one year follow-up assessment of the last patient is completed. The study is conducted by Hospices Civils de Lyon (HCL) in Lyon, France and more than 700 of the study´s total of 972 patients has been included so far.
Help employers find you! Check out all the jobs and post your resume.
NeuroVive Pharmaceutical AB (publ), a leading mitochondrial medicine company, announces that the ongoing international multicenter phase III study on the company´s drug candidate CicloMulsion® (the CIRCUS study) for the treatment of reperfusion injury in connection with heart attack is continuing according to plan and is approaching its final stage. If nothing unexpected occurs the study is estimated to be completed near the end of 2014, when the one year follow-up assessment of the last patient is completed. The study is conducted by Hospices Civils de Lyon (HCL) in Lyon, France and more than 700 of the study´s total of 972 patients has been included so far.
Help employers find you! Check out all the jobs and post your resume.